Betsy D. Holden
Betsy D. Holden's purchase track record
Betsy D. Holden has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/11/2026 | XRAY | $100K | +3.5% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage. XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Western Union renews Publix partnership amid dividend concerns. Western Union announced an extension of its agreement with Publix, aiming to support transaction growth in the Southeast. At the same time, the company’s dividend yield is reported near 15%, prompting analysts to question the sustainability of the payout. Recent commentary notes the high yield could lead to a dividend reduction, while the stock has outperformed the broader market recently.
Transaction History
| NNN | ▲ Buy | Grant | 1,217 | $59K | 7/31/2026 | View on chart |
| XRAY | ▲ Buy | Open Market | 10,086 | $100K | 6/11/2026 | View on chart |
| XRAY | ▲ Buy | Grant | 22,822 | $0 | 6/3/2026 | View on chart |
| NNN | ▲ Buy | Grant | 1,243 | $54K | 4/30/2026 | View on chart |
| WU | ▲ Buy | Grant | 20,921 | $0 | 3/2/2026 | View on chart |
| NNN | ▲ Buy | Grant | 1,276 | $53K | 1/30/2026 | View on chart |
| XRAY | ▲ Buy | Grant | 711 | $0 | 1/9/2026 | View on chart |
| NNN | ▲ Buy | Grant | 1,288 | $53K | 10/31/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 647 | $0 | 10/10/2025 | View on chart |
| NNN | ▲ Buy | Grant | 1,219 | $51K | 7/31/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 503 | $0 | 7/11/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 13,880 | $0 | 5/22/2025 | View on chart |
| NNN | ▲ Buy | Grant | 1,223 | $51K | 4/30/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 383 | $0 | 4/11/2025 | View on chart |
| NNN | ▲ Buy | Grant | 1,256 | $50K | 1/31/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 300 | $0 | 1/10/2025 | View on chart |
| NNN | ▲ Buy | Grant | 1,071 | $49K | 10/31/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 209 | $0 | 10/11/2024 | View on chart |
| NNN | ▲ Buy | Grant | 1,049 | $48K | 7/31/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 225 | $0 | 7/12/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 7,994 | $0 | 5/23/2024 | View on chart |
| NNN | ▲ Buy | Grant | 1,172 | $48K | 4/30/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 130 | $0 | 4/12/2024 | View on chart |
| NNN | ▲ Buy | Grant | 1,159 | $47K | 1/31/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 105 | $0 | 1/12/2024 | View on chart |
| NNN | ▲ Buy | Grant | 1,308 | $46K | 10/31/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 109 | $0 | 10/13/2023 | View on chart |
| NNN | ▲ Buy | Grant | 1,061 | $45K | 7/31/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 93 | $0 | 7/14/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 5,419 | $0 | 5/25/2023 | View on chart |
| NNN | ▲ Buy | Grant | 974 | $42K | 4/28/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 75 | $0 | 4/14/2023 | View on chart |
| WU | ▲ Buy | Grant | 12,058 | $0 | 2/23/2023 | View on chart |
| NNN | ▲ Buy | Grant | 880 | $41K | 1/31/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 83 | $0 | 1/13/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 6,382 | $0 | 11/15/2022 | View on chart |
| NNN | ▲ Buy | Grant | 1,636 | $68K | 10/31/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 64 | $0 | 10/14/2022 | View on chart |
| NNN | ▲ Buy | Grant | 1,434 | $67K | 7/29/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 49 | $0 | 7/8/2022 | View on chart |
| NNN | ▲ Buy | Grant | 1,457 | $67K | 4/29/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 36 | $0 | 4/8/2022 | View on chart |
| WU | ▲ Buy | Grant | 4,297 | $0 | 2/24/2022 | View on chart |
| NNN | ▲ Buy | Grant | 1,518 | $66K | 1/31/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 23 | $0 | 1/14/2022 | View on chart |
| NNN | ▲ Buy | Grant | 810 | $37K | 10/29/2021 | View on chart |
| XRAY | ▲ Buy | Grant | 26 | $2K | 10/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Truist covers NNN REIT, cites occupancy strategy
Truist Securities began coverage of NNN REIT with a Hold rating and set a price target of $45. Recent analyst commentary highlights the company's occupancy‑driven investment approach as a key strength. Dividend‑focused articles continue to list NNN among REITs expected to hold up despite higher interest rates. The stock is currently near its long‑standing support level of $43.09.
Truist covers NNN REIT, cites occupancy strategy. Truist Securities began coverage of NNN REIT with a Hold rating and set a price target of $45. Recent analyst commentary highlights the company's occupancy‑driven investment approach as a key strength. Dividend‑focused articles continue to list NNN among REITs expected to hold up despite higher interest rates. The stock is currently near its long‑standing support level of $43.09.